Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data
Primary central nervous system lymphoma (PCNSL) in patients living with HIV (PLWH) is a distinct entity; however, the management is adopted from patients without HIV. The study aims to examine the differences in presentation, treatment, and outcomes of PCNSL patients with or without HIV.
We retrospectively compared the characteristics of 144 patients with PCNSL with and without HIV, and analyzed factors associated with overall and progression-free survival. Results were compared to the Central Brain Tumor Registry of the United States (CBTRUS) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) system.
Among all patients with PCNSL, 19% had HIV. PLWH were younger (38 vs. 63 years; p < 0.01) and more likely to be African American (59% vs. 7%; p < 0.01) and male (74% vs. 49%; p = 0.02) than patients without HIV. PLWH were more likely to have multiple lesions (67% vs. 43%; p = 0.02), hemorrhage (59 vs. 37%; p = 0.03), and peripheral rim enhancement (57% vs. 7%; p < 0.01) on imaging; to receive palliative care (15% vs. 2%) or whole brain radiation (63% vs. 3%); and less likely to receive chemotherapy (22% vs. 95%) (p < 0.01). Twenty-four patients, none PLWH, underwent stem cell transplant. Not receiving transplant was an independent factor in mortality and disease progression. Our cohort of patients, compared to the national database, were younger (60 vs. 65 years), 58% were white vs. 75%, and had longer median overall survival 43 vs. 25 months.
Epidemiology, imaging, and treatment options for patients with PCNSL with and without HIV differ, but HIV was not an independent factor of mortality or disease progression. More efforts are needed to improve access to research and treatment options for PLWH with PCNSL.
KeywordsPrimary central nervous system lymphoma HIV Stem cell transplant Incidence Prognosis Treatment
We thank the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for editorial assistance.
QTO is supported by a Research Training Grant from the Cancer Prevention and Research Institute of Texas (CPRIT; RP160097T). Funding for the Central Brain Tumor Registry of the United States (CBTRUS) was provided by the U.S. Centers for Disease Control and Prevention (CDC) under Contract No. 2016-M-9030, the American Brain Tumor Association, The Sontag Foundation, Novocure, AbbVie, the Musella Foundation, Alex’s Lemonade Stand Foundation, as well as private, and in-kind donations. Contents are solely the responsibility of the authors and do not necessarily reflect the official views of the CDC or the VA.
Compliance with ethical standards
Conflict of interest
All authors have read and approved this manuscript and have no conflicts of interest to declare.
- 1.O’Neill BP, Decker PA, Tieu C, Cerhan JR (2013) The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol 88:997–1000CrossRefGoogle Scholar
- 13.Liu J, Wang Y, Liu Y, Liu Z, Cui Q, Ji N et al (2017) Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: analysis of 89 cases. Oncol Lett 14:5505–5512Google Scholar
- 15.Han CH, Batchelor TT (2017) Primary central nervous system lymphoma. Continuum 23(6, Neuro-oncology):1601–1618Google Scholar
- 16.Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B et al (2016) High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma: a randomized phase III trial (MATRix). BMC Cancer 16:282CrossRefGoogle Scholar
- 20.Garg N, Rayan J, Adams M, Downs R, Routbort M, McEnery K et al (2018) New search: an architecture for fast analytic search of electronic medical records. http://garglab.com/projects/data-mining/. Accessed 24 Oct 2017
- 22.Surveillance Epidemiology and End Results (SEER) Program (2017) SEER*Stat Database: Incidence—SEER 18 Regs Custom Data (with additional treatment fields), Nov 2016 Sub (2000–2014)—Linked To County Attributes—Total U.S., 1969–2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program. https://seer.cancer.gov/data-software/documentation/seerstat/nov2016/. Accessed 10 Feb 2018
- 23.National Cancer Institute (2018) Overview of the SEER Program. https://seer.cancer.gov/about/. Accessed 15 Jan 2018
- 24.Surveillance Epidemiology and End Results (SEER) Program (2015) Number of persons by race and hispanic ethnicity for SEER participants (2010 Census Data). https://seer.cancer.gov/registries/data.html. Accessed 25 April 2018
- 25.R Core Team (2018) R: a language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing. http://www.R-project.org/. Accessed 25 Apr 2018
- 26.Surveillance Epidemiology and End Results (SEER) Program (2018) SEER*Stat software version 8.3.5: National Cancer Institute, DCCPS, Surveillance Research Program. http://www.seer.cancer.gov/seerstat. Accessed 21 Jan 2018
- 30.DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N et al (2017) High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer 123:3073–3079CrossRefGoogle Scholar
- 33.Cranial radiotherapy or intensive chemotherapy with hematopoietic stem Cell rescue for primary central nervous system lymphoma in young patients (PRECIS). ClinialTrials.gov (2018) https://clinicaltrials.gov/ct2/show/NCT00863460. Accessed 9 Mar 2018
- 35.Centers for Disease Control and Prevention (2016) HIV Surveillance. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 4 Jun 2018